Company news

Oryzon Genomics SA news in 2022

Oryzon Genomics SA's news releases, calls and decks from 2022, newest first.

View company

ORYZON Awarded EU Grant to Further Explore the Role of Iadademstat in Oncological Immunotherapy Approaches

December 16, 2022

ORYZON Announces FDA Clearance of IND to Initiate a Collaborative Phase II Basket Study with Iadademstat in R/R Patients with Neuroendocrine Carcinomas (NECs)

November 9, 2022

ORYZON Announces Oral Data Presentation at the Upcoming 64th American Society of Hematology Annual Conference

November 7, 2022

ORYZON to Give Updates on Corporate Progress in November

November 4, 2022

ORYZON Reports Results and Corporate Update for Quarter Ended September 30, 2022

November 2, 2022

ORYZON to Give Updates on Corporate Progress in October

October 3, 2022

ORYZON to Present Preliminary Blinded Aggregate Safety Data From Vafidemstat’s Ongoing Phase IIb PORTICO Trial in Borderline Personality Disorder

September 16, 2022

ORYZON Collaborates with the CMT Research Foundation in the US

July 26, 2022

ORYZON Reports Results and Corporate Update for Half-Year Ending June 30, 2022

July 22, 2022

ORYZON Enters Cooperative Research and Development Agreement (CRADA) with U.S. National Cancer Institute to Develop Iadademstat in Different Cancers

July 19, 2022

ORYZON at EHA-2022: Iadademstat 42-month ALICE Data Demonstrate Robust Efficacy in Combination with Azacitidine in AML

June 10, 2022

ORYZON Awarded EU Seal of Excellence and Public Financing of $2M USD to Develop Iadademstat in Acute Myeloid Leukemia

June 7, 2022

ORYZON to Give Updates on Corporate Progress in June

June 6, 2022

ORYZON Reports Results and Corporate Update for Quarter Ended March 31, 2022

May 5, 2022

ORYZON Starts Preclinical Collaboration on Kabuki Syndrome with Kennedy Krieger Institute and Johns Hopkins University

May 3, 2022

ORYZON to Give Updates on Corporate Progress in February and March

February 14, 2022

ORYZON Reports Results and Corporate Update for Q4 and Year Ended December 31, 2021

February 7, 2022

ORYZON Announces New Senior VP of Clinical Development and Global Medical Affairs, Continuing its Expansion of US Corporate Activities

January 11, 2022

ORYZON Announces Approval for Serbian Arm of PORTICO, Vafidemstat’s Phase IIb Trial in Borderline Personality Disorder

January 4, 2022

Decks in 2022